Synergistic antitumor activity of lenalidomide with the BET bromodomain inhibitor CPI203 in bortezomib-resistant mantle cell lymphoma

Leukemia

Volumn 28, Issue 10, 2014, Pages 2049-2059

  Moros, A ^a   Rodriguez V ^a   Saborit Villarroya, I ^a   Montraveta, A ^a   Balsas, P ^a   Sandy, P ^b   Martinez A ^c   Wiestner, A ^d   Normant, E ^b   Campo, E ^a,c   Perez Galan P ^a   Colomer, D ^a,c   Roue G ^a  

^a INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^b Department of Structural Biology   (United States)

^c HOSPITAL CLÍNIC   (Spain)

^d NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B LYMPHOCYTE INDUCED MATURATION PROTEIN 1; BORTEZOMIB; BROMODOMAIN INHIBITOR; CPI 203; INTERFERON REGULATORY FACTOR 4; LENALIDOMIDE; MYC PROTEIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; INTERFERON REGULATORY FACTOR; INTERFERON REGULATORY FACTOR-4; PROTEASOME INHIBITOR; PYRAZINE DERIVATIVE; THALIDOMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER RESISTANCE; CARCINOGENICITY; CELL DIFFERENTIATION; CONTROLLED STUDY; DOWN REGULATION; DRUG POTENTIATION; GENE EXPRESSION PROFILING; GENE SILENCING; HUMAN; HUMAN CELL; IN VIVO STUDY; MANTLE CELL LYMPHOMA; MOUSE; NONHUMAN; PLASMA CELL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR VOLUME; UPREGULATION; XENOTRANSPLANTATION; ANALOGS AND DERIVATIVES; ANIMAL; CANCER TRANSPLANTATION; DRUG SCREENING; LYMPHOMA, MANTLE-CELL; METABOLISM; PROTEIN TERTIARY STRUCTURE; SCID MOUSE; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; CELL DIFFERENTIATION; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; GENE EXPRESSION PROFILING; HUMANS; INTERFERON REGULATORY FACTORS; LYMPHOMA, MANTLE-CELL; MICE; MICE, SCID; NEOPLASM TRANSPLANTATION; PROTEASOME INHIBITORS; PROTEIN STRUCTURE, TERTIARY; PROTO-ONCOGENE PROTEINS C-MYC; PYRAZINES; SIGNAL TRANSDUCTION; THALIDOMIDE;

EID: 84921725084     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2014.106     Document Type: Article

References (40)

1. Jares P, Colomer D, Campo E. Molecular pathogenesis of mantle cell lymphoma. J Clin Invest 2012; 122: 3416-3423
2. Perez-Galan P, Dreyling M, Wiestner A. Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era. Blood 2011; 117: 26-38
3. Orlowski RZ, Kuhn DJ. Proteasome inhibitors in cancer therapy: lessons from the first decade. Clin Cancer Res 2008; 14: 1649-1657
4. Xolalpa W, Perez-Galan P, Rodriguez MS, Roue G. Targeting the ubiquitin proteasome system: beyond proteasome inhibition. Curr Pharm Des 2013; 19: 4053-4093
5. Fisher RI, Bernstein SH, Kahl BS, Djulbegovic B, Robertson MJ, de VS et al. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 2006; 24: 4867-4874
6. Goy A, Bernstein SH, Kahl BS, Djulbegovic B, Robertson MJ, de VS et al. Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study. Ann Oncol 2009; 20: 520-525
7. O'Connor OA, Moskowitz C, Portlock C, Hamlin P, Straus D, Dumitrescu O et al. Patients with chemotherapy-refractory mantle cell lymphoma experience high response rates and identical progression-free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: results of a multicentre phase 2 clinical trial. Br J Haematol 2009; 145: 34-39
8. Weniger MA, Rizzatti EG, Perez-Galan P, Liu D, Wang Q, Munson PJ et al. Treatment-induced oxidative stress and cellular antioxidant capacity determine response to bortezomib in mantle cell lymphoma. Clin Cancer Res 2011; 17: 5101-5112
9. Roue G, Perez-Galan P, Mozos A, Lopez-Guerra M, Xargay-Torrent S, Rosich L et al. The Hsp90 inhibitor IPI-504 overcomes bortezomib resistance in mantle cell lymphoma in vitro and in vivo by down-regulation of the prosurvival ER chaperone BiP/Grp78. Blood 2011; 117: 1270-1279
10. Perez-Galan P, Mora-Jensen H, Weniger MA, Shaffer III AL, Rizzatti EG, Chapman CM et al. Bortezomib resistance in mantle cell lymphoma is associated with plasmacytic differentiation. Blood 2011; 117: 542-552
11. Iida S, Rao PH, Butler M, Corradini P, Boccadoro M, Klein B et al. Deregulation of MUM1/IRF4 by chromosomal translocation in multiple myeloma. Nat Genet 1997; 17: 226-230
12. Pathak S, Ma S, Trinh L, Eudy J, Wagner KU, Joshi SS et al. IRF4 is a suppressor of c-Myc induced B cell leukemia. PLoS One 2011; 6: e22628
13. Shaffer AL, Emre NC, Lamy L, Ngo VN, Wright G, Xiao W et al. IRF4 addiction in multiple myeloma. Nature 2008; 454: 226-231
14. Goy A, Sinha R, Williams ME, Kalayoglu Besisik S, Drach J, Ramchandren R et al. Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study. J Clin Oncol 2013; 31: 3688-3695
15. Vose JM, Habermann TM, Czuczman MS, Zinzani PL, Reeder CB, Tuscano JM et al. Single-agent lenalidomide is active in patients with relapsed or refractory aggressive non-Hodgkin lymphoma who received prior stem cell transplantation. Br J Haematol 2013; 162: 639-647
16. Witzig TE, Vose JM, Zinzani PL, Reeder CB, Buckstein R, Polikoff JA et al. An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma. Ann Oncol 2011; 22: 1622-1627
17. Zinzani PL, Vose JM, Czuczman MS, Reeder CB, Haioun CF, Polikoff JF et al. Long-term follow-up of lenalidomide in relapsed/refractory mantle cell lymphoma: subset analysis of the NHL-003 study. Ann Oncol 2013; 24: 2892-2897
18. Wang M, Fayad L, Wagner-Bartak N, Zhang L, Hagemeister F, Neelapu SS et al. Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial. Lancet Oncol 2012; 13: 716-723
19. Lopez-Girona A, Heintel D, Zhang LH, Mendy D, Gaidarova S, Brady H et al. Lenalidomide downregulates the cell survival factor, interferon regulatory factor-4, providing a potential mechanistic link for predicting response. Br J Haematol 2011; 154: 325-336
20. Yang Y, Shaffer III AL, Emre NC, Ceribelli M, Zhang M, Wright G et al. Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma. Cancer Cell 2012; 21: 723-737
21. Zhang LH, Kosek J, Wang M, Heise C, Schafer PH, Chopra R. Lenalidomide efficacy in activated B-cell-like subtype diffuse large B-cell lymphoma is dependent upon IRF4 and cereblon expression. Br J Haematol 2013; 160: 487-502
22. Zhu YX, Braggio E, Shi CX, Bruins LA, Schmidt JE, Van WS et al. Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. Blood 2011; 118: 4771-4779
23. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein S et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th edn. International Agency for Research on Cancer: Lyon, France, 2008
24. Shaffer AL, Wright G, Yang L, Powell J, Ngo V, Lamy L et al. A library of gene expression signatures to illuminate normal and pathological lymphoid biology. Immunol Rev 2006; 210: 67-85
25. Rosich L, Xargay-Torrent S, Lopez-Guerra M, Campo E, Colomer D, Roue G. Counteracting autophagy overcomes resistance to everolimus in mantle cell lymphoma. Clin Cancer Res 2012; 18: 5278-5289
26. Delmore JE, Issa GC, Lemieux ME, Rahl PB, Shi J, Jacobs HM et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 2011; 146: 904-917
27. Mertz JA, Conery AR, Bryant BM, Sandy P, Balasubramanian S, Mele DA et al. Targeting MYC dependence in cancer by inhibiting BET bromodomains. Proc Natl Acad Sci USA 2011; 108: 16669-16674
28. Devaiah BN, Lewis BA, Cherman N, Hewitt MC, Albrecht BK, Robey PG et al. BRD4 is an atypical kinase that phosphorylates Serine2 of the RNA polymerase II carboxy-terminal domain. Proc Natl Acad Sci USA 2012; 109: 6927-6932
29. King B, Trimarchi T, Reavie L, Xu L, Mullenders J, Ntziachristos P et al. The ubiquitin ligase FBXW7 modulates leukemia-initiating cell activity by regulating MYC stability. Cell 2013; 153: 1552-1566
30. Shaughnessy JD. Cancer: an unexpected addiction. Nature 2008; 454: 172-173
31. Feldman AL, Law M, Remstein ED, Macon WR, Erickson LA, Grogg KL et al. Recurrent translocations involving the IRF4 oncogene locus in peripheral T-cell lymphomas. Leukemia 2009; 23: 574-580
32. Mittrucker HW, Matsuyama T, Grossman A, Kundig TM, Potter J, Shahinian A et al. Requirement for the transcription factor LSIRF/IRF4 for mature B and T lymphocyte function. Science 1997; 275: 540-543
33. Dib A, Gabrea A, Glebov OK, Bergsagel PL, Kuehl WM. Characterization of MYC translocations in multiple myeloma cell lines. J Natl Cancer Inst Monogr 2008 25-31
34. Royo C, Salaverria I, Hartmann EM, Rosenwald A, Campo E, Bea S. The complex landscape of genetic alterations in mantle cell lymphoma. Semin Cancer Biol 21: 322-334
35. Clausen DM, Guo J, Parise RA, Beumer JH, Egorin MJ, Lazo JS et al. In vitro cytotoxicity and in vivo efficacy, pharmacokinetics, and metabolism of 10074-G5, a novel small-molecule inhibitor of c-Myc/Max dimerization. J Pharmacol Exp Ther 2010; 335: 715-727
36. Loven J, Hoke HA, Lin CY, Lau A, Orlando DA, Vakoc CR et al. Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell 2013; 153: 320-334
37. Cheng Z, Gong Y, Ma Y, Lu K, Lu X, Pierce LA et al. Inhibition of BET bromodomain targets genetically diverse glioblastoma. Clin Cancer Res 2013; 19: 1748-1759
38. Goupille O, Penglong T, Lefevre C, Granger M, Kadri Z, Fucharoen S et al. BET bromodomain inhibition rescues erythropoietin differentiation of human erythroleukemia cell line UT7. Biochem Biophys Res Commun 2012; 429: 1-5
39. Ott CJ, Kopp N, Bird L, Paranal RM, Qi J, Bowman T et al. BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia. Blood 2012; 120: 2843-2852
40. Zhao X, Lwin T, Zhang X, Huang A, Wang J, Marquez VE et al. Disruption of the MYC-miRNA-EZH2 loop to suppress aggressive B-cell lymphoma survival and clonogenicity. Leukemia 2013; 27: 2341-2350.